Navigation Links
Ventas to Present at the Citi 2008 Global Property CEO Conference
Date:2/26/2008

LOUISVILLE, Ky., Feb. 26 /PRNewswire-FirstCall/ -- Ventas, Inc. (NYSE: VTR) ("Ventas" or the "Company") announced today that its Chairman, President and Chief Executive Officer, Debra A. Cafaro, and Executive Vice President and Chief Investment Officer, Raymond J. Lewis, will make a presentation regarding the Company at the Citi 2008 Global Property CEO Conference in Palm Beach, Florida on Tuesday, March 4, 2008 at 1:15 p.m. Eastern Time.

Those wishing to access the presentation may dial in to the conference at 719-234-7878, passcode: 394890. Any written materials accompanying the presentation will be available on the Company's website at http://www.ventasreit.com at the time of the presentation and for one month thereafter.

Ventas, Inc. is a leading healthcare real estate investment trust. Its diverse portfolio of properties located in 43 states and two Canadian provinces includes seniors housing communities, skilled nursing facilities, hospitals and medical office and other properties. More information about Ventas can be found on its website at http://www.ventasreit.com.

Contacts: Debra A. Cafaro

Chairman, President and CEO

or

Richard A. Schweinhart

Executive Vice President and CFO

(502) 357-9000


'/>"/>
SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
2. Ventas Completes Previously Announced Sale of Common Stock
3. Ventas Enters Agreement to Sell Common Stock
4. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
5. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
6. Ventas Appoints Brush SVP - Senior Housing Development and Operations
7. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
8. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
9. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
10. Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference
11. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 1NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 2NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 3Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 1Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 2Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 3Gene Therapy Brings New Muscle to Monkeys 61251 1
Other Medicine Technology:Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6